Early Selective TAE to Severely Bleeding Peptic Ulcers After Their Initial Endoscopic Hemostasis
This study is ongoing, but not recruiting participants.
King Chulalongkorn Memorial Hospital
Information provided by (Responsible Party):
James Yun-wong Lau, Chinese University of Hong Kong
First received: June 9, 2010
Last updated: February 24, 2016
Last verified: February 2016
The aim of this study is to determine if early angiographic embolization can forestall recurrent bleeding in selected high risk ulcers after their initial endoscopic control; to validate prospectively the investigators proposed in selecting high risk ulcers for recurrent bleeding in spite of maximal endoscopic control and profound acid suppression using high dose intravenous infusion of proton pump inhibitor; to characterize the nature of bleeding arteries in severely bleeding peptic ulcers and determine the efficacy of angiographic embolization in the prevention of recurrent bleeding and to establish safety profile of angiographic embolization as an early elective treatment to bleeding peptic ulcers.
Procedure: No TAE
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
||Early Selective Angiographic Embolization to Severely Bleeding Peptic Ulcers After Their Initial Endoscopic Hemostasis - a Randomized Controlled Trial
Primary Outcome Measures:
- clinical re-bleeding [ Time Frame: within 30 days of therapy ] [ Designated as safety issue: No ]
Clinical rebleeding is defined by fresh hematemesis, fresh melena or hematochezia and signs of hypovolemic shock (systolic blood pressure of <90mmHg and pulse rate >110 per minute) and a drop in hemoglobin of > 2 g/dl per 24 hours despite adequate transfusion.
Rebleeding will be confirmed by an immediate endoscopy showing fresh blood in stomach or active bleeding from a previously seen ulcer. A clinical rebleeding will be independently reviewed by an adjudication panel.
Secondary Outcome Measures:
- death from all causes [ Time Frame: within 30 days of therapy ] [ Designated as safety issue: No ]
- transfusion requirement [ Time Frame: within 30 days of therapy ] [ Designated as safety issue: No ]
- hospital stay including Intensive Care Unit stay [ Time Frame: within 30 days of therapy ] [ Designated as safety issue: No ]
- further interventions either further TAE or surgery [ Time Frame: within 30 days of therapy ] [ Designated as safety issue: No ]
- hospital costs [ Time Frame: within 30 days of therapy ] [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Primary Completion Date:
||July 2014 (Final data collection date for primary outcome measure)
Active Comparator: TAE group
Patients will be undergone TAE after endoscopic hemostasis.
The procedure will be performed within 12 hours of endoscopic therapy. This is usually performed under conscious sedation
Other Name: Transarterial embolization
Active Comparator: No TAE group
No TAE procedure will be performed after endoscopic treatment.
Procedure: No TAE
No TAE procedure will be performed after endoscopic treatment
Endoscopic therapy is now the treatment of choice in patients with actively bleeding peptic ulcers and ulcers with non-bleeding visible vessels. Following endoscopic control of bleeding, we showed that the use of a high dose intravenous infusion of proton pump inhibitor (PPI) for 72 hours further reduced rate of recurrent bleeding [Lau NEJM 2000]. Recurrent bleeding still occurs in 8 to 10 percent of patients who receive the above treatment regime. The associated mortality following a rebleed is 4-10 fold higher when compared to those without recurrent bleeding. In a logistic regression model involving 1144 patients after successful endoscopic thermocoagulation to their bleeding peptic ulcers, we demonstrated that several factors independently predicted recurrent bleeding. They included hypotension, hemoglobin <10g/dl, fresh blood in the stomach, ulcer size > 2cm and active bleeding during endoscopy [Wong Gut 2003]. When we applied this model in a cohort of 945 patients who underwent endoscopic control of bleeding to their ulcers and adjunctive use of high dose intravenous PPI, 275 belonged to the high risk group. Of them, rebleeding leading to surgery or death occurred in 46 patients (16.7%)[Chiu DDW 2007]. Endoscopic treatment to bleeding peptic ulcers has its own limit. In an ex vivo bleeding model using canine mesenteric arteries, endoscopic thermocoagulation could only consistently seal arteries up to 2 mm in size [Johnson Gastro 1987]. Trans-arterial angiography allows clinicians to study and characterize bleeding arteries underneath peptic ulcers. In ulcers that erode into major arteries such as the gastro-duodenal artery complex and branches from left gastric artery, angiography complements endoscopic therapy in the form of selective coiling of the bleeding artery. Trans-arterial angiographic coiling can provide definitive control of bleeding from larger arteries i.e. > 2 mm in size. In cohort studies, trans-arterial angiographic coiling has been shown to compare favorably to surgery, and is less invasive in the control of severe bleeding in peptic
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Actively bleeding peptic ulcers (Forrest I), NBVV or Forrest IIa ulcer,
- Successful endoscopic hemostasis by combination treatment of injected epinephrine followed by either 3.2mm heat probe 30J (4 continuous pulses) or hemo-clipping (at least 2 clips) And one of the followings
- Spurting hemorrhage during endoscopy;
- Ulcer >= 2 cm is determined by an opened biopsy forceps;
- Hb on admission of < 9 g/dl; or
- Hypotension prior to endoscopy defined by SBP of <90 mmHg AND HR of >110 bmp
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01142180
|Endoscopy Centre, Prince of Wales Hospital
|Hong Kong, China |
Chinese University of Hong Kong
King Chulalongkorn Memorial Hospital
||James Y LAU, MD
||Chinese University of Hong Kong
||James Yun-wong Lau, Professor, Chinese University of Hong Kong
History of Changes
|Other Study ID Numbers:
|Study First Received:
||June 9, 2010
||February 24, 2016
||Hong Kong: Department of Health
Keywords provided by Chinese University of Hong Kong:
Bleeding peptic ulcer
Trans-arterial angiographic embolization
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 26, 2016
Peptic Ulcer Hemorrhage
Digestive System Diseases